| 晚期卵巢癌化疗中CA125 下降的临床意义 |
| |
| 引用本文： | 胡元晶, 李 娜, 曲芃芃. 晚期卵巢癌化疗中CA125 下降的临床意义[J]. 中国肿瘤临床, 2010, 37(18): 1062-1064. DOI: 10.3969/j.issn.1000-8179.2010.18.013 |
| |
| 作者姓名： | 胡元晶 李娜 曲芃芃 |
| |
| 作者单位： | 作者单位:天津市中心妇产科医院妇瘤科(天津市300100) |
| |
| 摘 要： | 目的：比较晚期卵巢癌TP方案和PAC 方案化疗血清CA125 下降情况。评价化疗中CA125 下降情况对晚期卵巢癌生存预后的预测作用。方法：122 例和95例Ⅱc～Ⅳ期卵巢癌患者肿瘤细胞减灭术后分别采用TP和PAC 方案化疗。每一个疗程化疗前取静脉血免疫法测定血清CA125，计算CA125 半衰期使用单项分割Log 减低法。t 检验用于比较两治疗组间CA125 半衰期和CA125 最低值间差异，应用单因素（Kaplan-Meier）和多因素Cox 回归分析全部患者化疗中CA125 下降情况对无进展生存和总生存期的意义。结果：两化疗组间CA125 半衰期和最低值间无显著性差异。单变量分析全部患者CA125 半衰期和最低值是无进展生存和总生存期的预后指标，而不同化疗方案及化疗前CA125 水平不是预后指标。多变量分析结果显示：CA125 半衰期，残存病灶，CA125 最低值是无进展生存和总生存期的独立预后指标。结论：晚期卵巢癌应用TP和PAC 方案化疗CA125 下降无显著性差异；一线化疗中CA125 半衰期和最低值是晚期卵巢癌独立的预后因素。
|
| 关 键 词： | CA125 晚期卵巢癌 化疗 生存期 |
| 收稿时间： | 2010-01-23 |
| 修稿时间： | 2010-03-28 |
Clinical Significance of CA125 Regression in Chemotherapy for Advanced Ovarian Cancer |
| |
| HU Yuanjin, LI Na, QU Pengpeng. Clinical Significance of CA125 Regression in Chemotherapy for Advanced Ovarian Cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 37(18): 1062-1064. DOI: 10.3969/j.issn.1000-8179.2010.18.013 |
| |
| Authors: | HU Yuanjin LI Na QU Pengpeng |
| |
| Affiliation: | Gynecologic Oncology Department, Tianjin Central Hospital of Obstetrics and Gynecology, Tianjin300100, China |
| |
| Abstract: | Objective: To assess the serum CA 125 regression in advanced ovarian carcinoma patients treated with paclitaxel/platinum (TP) and platinum/ epirubicin/ ifosafamide (PAC) during early chemotherapy and evaluate the relationship between survival and CA125 regression during first-line chemotherapy. Methods:This retrospective investigation assessed 122 and 95patients with stagesⅡc- Ⅳovarian carcinoma, respectively, who underwent initial surgery followed by TP or PAC chemotherapy. Only epithelial ovarian cancers were included. CA125 half-life was calculated by mono-compartmental logarithmic regression. The nadir CA 125 concentration of each patient was also studied. Additionally, t-test was used in comparing CA125 half-life and nadir CA125 between the two groups. Survival analyses for progression-free survival (PFS) and overall survival (OS) were performed by using univariate (Kaplan-Meier) and multivariate (Cox) models on the data. Results: There was no significant difference in CA125 half-life and nadir CA125 concentration between the two groups (P >0.05). CA125 half-life and nadir CA125 concentration had a univariate prognostic value for PFS and OS (P<0.0001) in all of the patients. However pre-chemotherapy CA125 and different chemotherapy agents were not prognostic factors for PFS and for OS ( P>0.05, for each). In Cox model, CA125 half-life (P=0.0006), residual tumor (P<0.0001), and nadir concentration ( P=0.0032) were significant prognostic factors for DFS. For OS, CA125 half-life ( P=0.0013), residual tumor (P<0.0001), and nadir concentration ( P=0.0118) were also the significant prognostic factors. Conclusion : There is no significant difference in serum CA125 regression between patients who are treated with PAC and PT during early chemotherapy. CA125 half-life and nadir CA 125 concentration are independent prognostic factors in advanced ovarian cancer. |
| |
| Keywords: | CA125 |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载免费的PDF全文 |
|
